BioSpace News Archive

Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its first inflammatory bowel disease (IBD) model and has achieved the next milestone, target validation.

BioVie Inc., today announced that three abstracts highlighting results of its Phase 2, open-label study of NE3107 in patients with Alzheimer’s Disease (AD) were accepted for presentation at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD).

Travere Therapeutics, Inc. and NephCure Kidney International today announced the launch of RKD & Me, a new public awareness campaign that spotlights the real stories of people living with rare kidney disease to amplify their unique lived experiences.

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. to discuss the positive initial efficacy data of the Company’s phase I/IIaa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer.

Grace Breeding Ltd. announced a strategic research and development collaboration with the University of Londrina, based in Paraná State, Brazil.

Alcon today announced the Canadian launch of its latest innovation to treat patients with dry eye: the Systane MD iLux 2MD Meibomian Gland Dysfunction (MGD) Thermal Pulsation System.

Reistone Biopharma (Reistone) today announced positive results from a Phase III study – QUARTZ3 (NCT04875169) evaluating the efficacy and safety of once daily Ivarmacitinib as monotherapy in adults and adolescents with moderate-to-severe atopic dermatitis (AD).

GUELPH, ON, Nov. 15, 2022 /PRNewswire/ - BIOREM Inc. announced its results for the three and nine-month periods ended September 30, 2022.

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company) today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (“SFN”) taking place November 12-16, 2022, in San Diego, CA.

CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced the close of an oversubscribed $120 million Series E financing round.